Nasdaq
$18.00▼ 1.37%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $975.3MShares out 54.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.5After-hours26.10.06 07:524Ownership#●●●#●●●
Vor Biopharma Inc.
RA Capital Healthcare Fund LP, a major shareholder of Vor Biopharma Inc., reported a change in its beneficial ownership of securities as of October 2, 2026. This filing is a Form 4 statement detailing the transaction.…more
$18.00-1.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.4After-hours26.09.05 05:30S-3ASROffering
Vor Biopharma Inc.
Vor Biopharma has filed an automatic shelf registration statement on Form S-3ASR, allowing the company to offer and sell common stock, preferred stock, debt securities, warrants, and units from time to time. This filing serves as a preliminary step for potential future capital raising, with specific terms and offering sizes to be determined and disclosed in subsequent prospectus supplements.…more
$18.00-1.37%vs prev closeView filingShare - 8.26After-hours26.08.27 07:284Ownership
Vor Biopharma Inc.
Major shareholder RA Capital Healthcare Fund LP and associated executives of Vor Biopharma filed a Form 4 on August 26, 2026, reporting changes in beneficial ownership as of August 24, 2026. This filing serves as the official record for the reported changes in the insiders' equity holdings.…more
$18.00-1.37%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:05Bullish#●●●#●●●#●●●
Vor Bio Reports Positive 2-Year Phase 3 Results for Telitacicept in IgA Nephropathy…more
Vor Bio announced that its Phase 3 trial demonstrated durable kidney function preservation and sustained proteinuria reduction over 104 weeks. While these findings strengthen the clinical profile of telitacicept, the company still faces the path toward global regulatory approval.…more
$18.00-1.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5After-hours26.10.06 07:00
●●●●●●●● ●●●●● ●●●●●●
Vor Bio announced the grant of stock options and restricted stock units to nine newly hired employees as a material inducement for employment. This action follows standard Nasdaq listing rules regarding compensation for new personnel.…more
$18.00-1.37%vs prev close - 9.29Pre-market26.09.29 21:07
●●●●●●●● ●●●●● ●●●●●●
Vor Bio's partner RemeGen announced that over 95% of participants in a Phase 3 trial for telitacicept achieved significant improvement in generalized myasthenia gravis symptoms. The findings were presented at the AANEM Annual Meeting, highlighting the drug's clinical potential.…more
$18.00-1.37%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report